Oksana Koneva

Kura Oncology to present new clinical data on combination therapies for acute myeloid leukemia at 68th ASH meeting

Kura Oncology to present new clinical data on combination therapies for acute myeloid leukemia at 68th ASH meeting
Kura Oncology presents AML data at ASH

Kura Oncology announced it will share several new abstracts at the 68th American Society of Hematology (ASH) Annual Meeting. The presentations, in collaboration with Kyowa Kirin, will include first results from clinical studies on combination treatment strategies for acute myeloid leukemia (AML).

The company is expected to introduce new clinical data, highlighting its ongoing research efforts in AML therapies. Details on the specific findings will be presented at the ASH event.

Kura Oncology recently began enrolling patients in its FIT-001 Phase 1b trial, investigating a farnesyl transferase inhibitor combination therapy in advanced renal cell carcinoma. The company also scheduled an investor webcast to discuss the launch of Caspian Therapeutics and share KO-7246 preclinical data. These developments reflect Kura's ongoing expansion of its clinical research portfolio.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.